Home » Abraxane Meets Primary Endpoint in Phase III Trial
Abraxane Meets Primary Endpoint in Phase III Trial
Abraxis BioScience, Inc. Wednesday announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with
Taxol (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant
improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer, as assessed
by independent radiologist review.
StreetInsider
StreetInsider
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May